Morgan Stanley’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Morgan Stanley’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.71K	Hold	146,439	–	–	﹤0.01%	7210
2025 Q4	$4.57K	Hold	146,439	–	–	﹤0.01%	7086
2025 Q3	$3.43K	Hold	146,439	–	–	﹤0.01%	7183
2025 Q2	$4.88K	Hold	146,439	–	–	﹤0.01%	7038
2025 Q1	$3.81K	Hold	146,439	–	–	﹤0.01%	7053
2024 Q4	$11K	Hold	146,439	–	–	﹤0.01%	6766
2024 Q3	$5.27K	Hold	146,439	–	–	﹤0.01%	6905
2024 Q2	$6.94K	Sell	146,439 -2,500	-2%	-$93	﹤0.01%	6774
2024 Q1	$4.47K	Sell	148,939 -148,939	-50%	-$4.01K	﹤0.01%	6919
2023 Q4	$9K	Buy	297,878 +148,939	+100%	+$8.97K	﹤0.01%	6856
2023 Q3	$10.4K	Hold	148,939	–	–	﹤0.01%	6723
2023 Q2	$15.5K	Hold	148,939	–	–	﹤0.01%	6644
2023 Q1	$5.36K	Hold	148,939	–	–	﹤0.01%	7034
2022 Q4	$7K	Hold	148,939	–	–	﹤0.01%	7057
2022 Q3	$9K	Hold	148,939	–	–	﹤0.01%	7118
2022 Q2	$22K	Sell	148,939 -1,907	-1%	-$435	﹤0.01%	6939
2022 Q1	$72K	Buy	150,846 +119,439	+380%	+$101K	﹤0.01%	6508
2021 Q4	$56K	Buy	+31,407	New	+$57.6K	﹤0.01%	6757

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Morgan Stanley's SABSW Position: Q1 2026 in Review

Morgan Stanley held its SAB Biotherapeutics Warrant (SABSW) position steady in Q1 2026 at 146,439 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #7210.

Morgan Stanley first reported a position in SABSW in Q4 2021 and has held it in 18 quarters since. The position peaked at $72K in Q1 2022. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

Morgan Stanley held 146,439 shares of SAB Biotherapeutics Warrant worth $3.71K as of Q1 2026.
Morgan Stanley left its SAB Biotherapeutics Warrant share count unchanged in Q1 2026.
SAB Biotherapeutics Warrant made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7210 holding.
Morgan Stanley first reported a position in SAB Biotherapeutics Warrant in Q4 2021 and has held it in 18 quarters since.
Morgan Stanley's SAB Biotherapeutics Warrant position peaked at $72K in Q1 2022.
6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.